Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Arcutis Biotherapeutics Inc. has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners, showing a slight concentration of the workload. The portfolio spans 3 distinct art units, reflecting a range of technical classifications for the company's biopharmaceutical filings. This distribution across 3 distinct art units requires the applicant to account for multiple technical requirements across its 5 pending matters. Practitioners should develop strategies that address the specific standards of each of the 3 distinct art units involved.
SOROUSH, LAYLA is the busiest examiner, currently handling 2 pending office actions. This examiner manages a significant portion of the 5 total pending actions for the company. With 4 distinct examiners and 3 distinct art units involved, the company's prosecution strategy must account for multiple examiner styles. Practitioners should note that the 5 pending office actions are reviewed by 4 different individuals, which provides some diversity in the feedback received from the patent office. The 3 distinct art units indicate that the company's biotechnology research is being evaluated by several specialized divisions. This structure requires a multifaceted approach to resolve the 5 pending office actions while maintaining technical consistency across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 2 | 40.5% | +43.4% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
| JOSEPH, JANET | 1 | 40.0% | +51.3% |
| WELLES, COLMAN THOMAS | 1 | 29.2% | +64.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18146112 | Topical Aerosol Foams | WELLES, COLMAN THOMAS | 28d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18146112 | Topical Aerosol Foams | WELLES, COLMAN THOMAS | 28d overdue |
| 18827222 | DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONS | SOROUSH, LAYLA | — |
| 18795580 | LAURETH-4 CONTAINING TOPICAL FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 18789083 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | SOROUSH, LAYLA | — |
| 18037316 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY | JOSEPH, JANET | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1611 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18827222 | DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONS | SOROUSH, LAYLA | 1622 | §103DP | Final Rejection | — | Pending | Sep 06, 2024 |
| 18795580 | LAURETH-4 CONTAINING TOPICAL FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — | §103DP | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18789083 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | SOROUSH, LAYLA | — | §102§103DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18037316 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY | JOSEPH, JANET | 1611 | §102§103DP | Non-Final OA | — | Pending | May 16, 2023 |
| 18146112 | Topical Aerosol Foams | WELLES, COLMAN THOMAS | 1612 | §103 | Final Rejection | 28d overdue | Pending | Dec 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial